OakChart

Jazz Pharmaceuticals plc

JAZZHealthcare·Biotechnology·Ireland·Large·NASD·Nov 11 • 3:59 PM ET

248.24+2.81 (1.14%)
2026-11-12 05:20 CET
Market cap
15,934.28 USD m
Revenue, TTM
4,718.13 USD m
Net income, TTM
205.95 USD m
Free cash flow, TTM
1,621.79 USD m
EPS diluted, TTM
2.95
P/E
84.20
Compare

Price

JAZZ against its 20, 50 and 200-day averages
2050200miss
175.00200.00225.00250.002.4M4.7MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26JAZZclose 248.2420-day 220.3550-day 229.35200-day 219.26248.2452w high

6.8% under the 52-week high of 266.38 on 25 Aug 2026. 52-week low 132.10 on 11 Nov 2025. Last 15 sessions, 23.1% high to low

Volume 0.67× normal · the line is the 50-bar volume average

Profile

JAZZ
52-week range, 86% of the way up
132.1266.38

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

IndexRUI
Employees2890
IPOJun 01, 2007
Beta0.35
ATR, 14d7.52
Rel volume0.67
Short float9.40%
Insider own3.94%
Inst own102.18%

Snapshot

6 groups

Valuation

IndexRUI
Market Cap15.93B
Enterprise Value18.72B
Income205.95M
Sales4.72B
Book/sh65.39
Cash/sh44.50
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees2890
IPOJun 01, 2007

Ratios

P/E84.20
Forward P/E9.31
PEG0.19
P/S3.38
P/B3.80
P/C5.58
P/FCF9.83
EV/EBITDA9.92
EV/Sales3.97
Quick Ratio1.64
Current Ratio1.82
Debt/Eq1.35
LT Debt/Eq1.10
Option/ShortYes / Yes

Earnings

EPS (ttm)2.95
EPS next Y26.67
EPS next Q6.97
EPS this Y78.79%
EPS next Y78.00%
EPS next 5Y49.00%
EPS past 3/5Y-17.69% -
Sales past 3/5Y5.26% 12.54%
EPS Y/Y TTM161.19%
Sales Y/Y TTM13.48%
EPS Q/Q-283.08%
Sales Q/Q10.38%
EarningsNov 02 AMC
EPS/Sales Surpr.3.78% 2.88%

Ownership

Insider Own3.94%
Insider Trans-7.48%
Inst Own102.18%
Inst Trans-0.35%
ROA1.76%
ROE5.05%
ROIC2.34%
Gross Margin74.60%
Oper. Margin24.77%
Profit Margin4.37%
SMA2012.66%
SMA508.23%
SMA20013.22%
Trades-

Technical

Shs Outstand64.10M
Shs Float61.66M
Short Float9.40%
Short Ratio6.56
Short Interest5.80M
52W High266.38 -6.81%
52W Low132.10 87.92%
Volatility3.41% 3.08%
ATR (14)7.52
RSI (14)67.98
Beta0.35
Rel Volume0.67
Avg Volume883.37K
Volume592,955

Performance

Perf Week5.79%
Perf Month17.99%
Perf Quarter0.97%
Perf Half Y6.85%
Perf YTD46.02%
Perf Year81.05%
Perf 3Y106.52%
Perf 5Y83.22%
Perf 10Y119.47%
Recom1.42
Target Price300.19
Prev Close245.43
Price248.24
Change %1.14%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Sep 30, 2026InitiatedCCitigroupBuy$325+30.9%
Sep 24, 2026ResumedGGoldmanBuy$337+35.8%
Jul 17, 2026InitiatedCCanaccord GenuityBuy$290+16.8%
Jun 09, 2026ResumedTTruistBuy$256+3.1%
May 22, 2026InitiatedBBernsteinMkt Perform$229-7.8%
May 19, 2026UpgradeUUBSNeutral → Buy$307+23.7%
Apr 10, 2026ResumedRRaymond JamesOutperform$227-8.6%
Feb 27, 2026InitiatedBBarclaysOverweight$224-9.8%
Nov 24, 2025DowngradeUUBSBuy → Neutral$188-24.3%
Jul 15, 2025InitiatedDDeutsche BankBuy$152-38.8%

Peers

Mkt cap
TickerCompanyMkt cap
HRMYHarmony Biosciences Holdings Inc2.01B
AXSMAxsome Therapeutics Inc7.85B
ALKSAlkermes plc8.05B
INCYIncyte Corp24.92B
EXELExelixis Inc17.25B
NBIXNeurocrine Biosciences Inc17.65B
BMRNBiomarin Pharmaceutical Inc11.30B
CORTCorcept Therapeutics Inc8.16B
SUPNSupernus Inc6.12B
UTHRUnited Therapeutics Corp25.37B

Insider trading

latest 14 of 100
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
COZADD BRUCE CDirectorNov 06 '26Option Exercise136.1886,50011,779,570426,375Nov 10 04:46 PM
COZADD BRUCE CDirectorNov 06 '26Sale235.9568,80816,235,517357,567Nov 10 04:46 PM
Carr PatriciaSVP, Chief Accounting OfficerNov 04 '26Option Exercise140.031,250175,0387,925Nov 06 05:19 PM
Carr PatriciaSVP, Chief Accounting OfficerNov 04 '26Sale231.361,413326,9106,512Nov 06 05:19 PM
BRUCE COZADDDirectorNov 06 '26Proposed Sale235.9568,80816,235,516Nov 06 04:41 PM
GALA RENEE DPresident & CEONov 03 '26Sale225.371,000225,370140,394Nov 05 06:28 PM
COZADD BRUCE CDirectorNov 02 '26Sale215.846,0001,295,040339,875Nov 04 06:35 PM
PATRICIA CARROfficerNov 04 '26Proposed Sale231.361,413326,910Nov 04 04:05 PM
RENEE D GALAOfficerNov 03 '26Proposed Sale225.371,000225,370Nov 03 04:23 PM
Bruce C CozaddOfficerNov 02 '26Proposed Sale215.846,0001,295,040Nov 02 04:27 PM
ANNE O'RIORDANDirectorOct 08 '26Proposed Sale228.5514,6873,356,714Oct 08 04:04 PM
GALA RENEE DPresident & CEOOct 06 '26Sale236.402,000472,800141,394Oct 07 05:44 PM
RENEE D GALAOfficerOct 06 '26Proposed Sale236.402,000472,800Oct 06 04:20 PM
COZADD BRUCE CDirectorOct 01 '26Sale230.336,0001,381,980345,875Oct 05 04:18 PM

Held by

AUM
TickerCompanyAUM
IJHiShares Core S&P Mid-Cap ETFAUM: 124.48B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
VBRVanguard Morningstar Small-Cap Value ETFAUM: 37.76B
VFLOVictoryShares Free Cash Flow ETFAUM: 12.50B
XMMOInvesco S&P MidCap Momentum ETFAUM: 6.37B
VXFVanguard Extended Market Index ETFAUM: 30.47B
MDYState Street SPDR S&P MIDCAP 400 ETF TrustAUM: 26.22B
IJKiShares S&P Mid-Cap 400 Growth ETFAUM: 10.46B
DFATU.S. Targeted Value Portfolio-ETF Class SharesAUM: 14.47B

News

latest 14 of 200
  • Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences (PR Newswire) +7.13%
  • 4 Biotech Stocks Seeing Unusual Options Volume Today (Schaeffer's Research)
  • Jazz: Q3 Earnings Snapshot (Associated Press)
  • Jazz Pharmaceuticals Beats As Revenue Guidance Rises Again, But Slowing Growth And An Actio Charge Leave The Stock At A Crossroads (Earnings Whispers)
  • Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results (PR Newswire)
  • Jazz Pharmaceuticals to Highlight Neuro-Oncology Clinical Research at SNO 2026 (PR Newswire)
  • With Setara, the team behind Actio opens its second act (BioPharma Dive)
  • Jazz Must Prove Its Xywav Surge Is Durable After A Raise The Market Has Shrugged Off (Earnings Whispers)
  • Ziihera (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026 (PR Newswire)
  • Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026 (PR Newswire)
  • Cathie Wood-Backed Biotech IPO Pops in Debut (Barrons.com)
  • Former Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera (NASDAQ: ENTX) (FinanceWire)
  • Target upgraded, Moderna downgraded: Wall Street's top analyst calls (The Fly)
  • Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences (PR Newswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-02-3.880-4.033-7.4801,2431,20813
2026Q22026-08-035.7106.1752.7781,2081,11417
2026Q12026-05-056.3404.6414.4341,069978.6614
2025Q42026-02-246.6406.5183.2071,1981,16514
2025Q32025-11-058.1305.9474.0811,1261,11117
2025Q22025-08-05-8.250-7.606-11.7411,0461,04714
2025Q12025-05-061.6804.658-1.518897.84983.7716
2024Q42025-02-256.6005.8623.1071,0881,05816
2024Q32024-11-066.6105.4983.4041,0551,03717
2024Q22024-07-315.3004.9222.4211,0241,01017
2024Q12024-05-012.6804.179-0.234901.98953.9716
2023Q42024-02-285.0205.1851.3511,0121,00715
2023Q32023-11-084.8404.9332.059972.14968.4116
2023Q22023-08-094.5104.4451.420957.32941.9915
2023Q12023-05-103.9504.2400.941892.81897.3916
2022Q42023-03-01-0.0700.883-3.818972.12975.4814

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY16.23015.9009.0942,1362,141
2020FY12.46012.5974.2222,3642,332
2021FY16.23015.667-5.5233,0943,062
2022FY13.20013.558-3.5833,6593,659
2023FY18.29018.4986.1023,8343,834
2024FY20.90020.3078.6494,0694,039
2025FY8.3808.230-5.8404,2684,238
2026FY-14.983--4,805
2027FY-26.670--5,055
2028FY-27.722--5,429
2029FY-32.913--6,044
2030FY-34.460--6,267

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-10181701,2841,2511,323
2026Q4S2026-11-03181601,2821,2341,323
2026Q4S2026-11-0218501,2441,2151,315
2026Q4S2026-10-2818501,2411,2151,296
2026Q4S2026-10-2718401,2401,2151,296
2026Q4S2026-10-2618401,2401,2131,296
2026Q4S2026-10-1818301,2381,1831,296
2026Q4S2026-10-15181411,2381,1831,296
2026Q4S2026-10-09181411,2361,1831,290
2026Q4S2026-10-07181411,2351,1831,290
2026Q4S2026-10-05181411,2351,1831,290
2026Q4S2026-10-03181411,2361,1831,290
2026Q4S2026-10-02181511,2361,1831,290
2026Q4S2026-09-30181511,2341,1831,290

Estimate history

EPS, annual7.967.3039.0944.222-5.523-3.5836.1028.649-5.842.9482
Period201720182019202020212022202320242025TTM
EPS, quarterly3.4043.107-1.518-11.7414.0813.2074.4342.778-7.471
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual1618.6931890.9222161.7612363.5673094.2383659.3743834.2044068.954267.5864718.13
Period201720182019202020212022202320242025TTM
Sales, quarterly1054.9691088.173897.8411045.7121126.1071197.9261068.91208.31243
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual59.89857.50456.1456.17161.63363.21462.25560.63161.43564.1
Period201720182019202020212022202320242025MRQ
Shares, quarterly60.44360.63161.62360.6460.7461.43562.764.864.1
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue4,718.134,267.594,068.953,834.203,659.373,094.242,363.572,161.761,890.92
Cost of Goods Sold Incl. D&A1,198.471,157.961,073.031,043.861,139.69966.53408.50482.74323.04
Gross Profit3,519.663,109.632,995.922,790.342,519.692,127.711,955.071,679.021,567.88
Selling, General and Administrative Excl. Other2,351.122,358.512,269.292,131.061,799.521,728.431,189.611,036.67909.65
Research and Development829.31782.74884.00849.66590.45505.75335.38299.73226.62
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income1,168.54751.12726.63659.28720.17399.28765.46642.35658.23
Interest Expense260.31279.54339.60351.12297.10278.0896.3192.7677.33
Unusual Expense877.011,169.3024.4467.16806.30248.59367.55116.1744.07
Net Income Before Taxes259.77-627.86470.35297.93-372.78-112.84275.10454.30529.46
Income Taxes53.66-272.44-91.43-119.91-158.65216.1233.52-73.1580.16
Consolidated Net Income205.95-356.15560.12414.83-224.06-329.67238.62523.37447.10
Net Income From Continuing Operations205.95-356.15560.12414.83-224.06-329.67238.62523.37447.10
Net Income205.95-356.15560.12414.83-224.06-329.67238.62523.37447.10
EPS (Recurring)12.677.588.916.755.44-2.618.7710.517.81
EPS (Basic, Before Extraordinaries)3.65-5.849.066.55-3.58-5.524.289.227.45
EPS (Diluted)2.95-5.848.656.10-3.58-5.524.229.097.30
EBITDA1,887.101,447.421,386.701,297.981,349.64951.761,043.711,012.50874.97
Non-Operating Income (Expense)228.5669.86107.7756.9210.4414.55-26.5220.88-7.38
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense214.66239.32207.49186.83180.94155.05108.1694.8585.21
Price To Earnings Ratio84.2084.2017.74204.08--39.2616.4016.97
Price To Sales Ratio3.172.432.002.312.722.463.953.974.01
Gross Margin74.6072.8773.6372.7868.8668.7682.7277.6782.92
Operating Margin24.7717.6017.8617.1919.6812.9032.3929.7134.81
Net Margin4.37-8.3513.7710.82-6.12-10.6510.1024.2123.64
Shares Outstanding64.1061.4460.6362.2663.2161.6356.1756.1457.50
Market Capitalization15,934.2815,934.287,444.987,743.7010,031.167,831.239,195.608,445.227,477.52

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue1,243.001,208.301,068.901,197.931,126.111,045.71897.841,088.17
Cost of Goods Sold Incl. D&A282.40286.40306.40323.27297.25278.37259.07287.62
Gross Profit960.60921.90762.50874.66828.86767.34638.77800.56
Selling, General and Administrative Excl. Other585.60596.70548.70620.12667.35548.37694.66609.79
Research and Development211.90207.50196.00213.91198.20189.97180.65240.50
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income375.00325.20213.80254.53161.51218.97-55.89190.77
Interest Expense68.8062.4063.3065.8166.7766.0680.9182.20
Unusual Expense788.3078.108.502.11110.82892.97-8.6123.93
Net Income Before Taxes-458.90211.00299.20208.479.04-735.55-109.81133.22
Income Taxes24.5018.106.104.96-242.42-17.17-17.81-57.91
Consolidated Net Income-483.40192.80293.10203.45251.41-718.47-92.54191.12
Net Income From Continuing Operations-483.40192.80293.10203.45251.41-718.47-92.54191.12
Net Income-483.40192.80293.10203.45251.41-718.47-92.54191.12
EPS (Recurring)1.063.574.523.235.34-1.53-1.623.38
EPS (Basic, Before Extraordinaries)-7.473.054.743.334.14-11.74-1.523.16
EPS (Diluted)-7.472.784.433.214.08-11.74-1.523.11
EBITDA553.90504.30395.20433.70339.75392.98108.98359.19
Non-Operating Income (Expense)23.2026.30157.2021.8625.114.5018.3848.58
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense58.2054.3044.7057.4671.5152.2458.1255.45
Price To Earnings Ratio84.20----14.3114.2717.74
Price To Sales Ratio3.173.632.822.531.951.591.861.86
Gross Margin77.2876.3071.3473.0173.6073.3871.1573.57
Operating Margin30.1726.9120.0021.2514.3420.94-6.2317.53
Net Margin-38.8915.9627.4216.9822.33-68.71-10.3117.56
Shares Outstanding64.1064.8062.7061.4460.7460.6461.6260.63
Market Capitalization15,934.2815,137.1611,637.9710,330.077,994.836,421.437,539.947,444.98

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments2,441.902,992.861,626.31881.48591.452,132.771,077.34824.62616.53
Short Term Receivables830.75716.76705.79651.49563.36396.49355.99263.84224.13
Inventories416.96480.44597.04714.061,072.7295.4078.6152.9643.24
Other Current Assets476.44438.95334.78267.97334.89214.91118.3392.5984.37
Total Current Assets4,166.044,629.033,263.922,515.012,562.422,839.571,630.271,234.01968.28
Net Property, Plant & Equipment258.74227.00234.99301.38343.42257.10270.89200.36170.08
Total Investments and Advances4.304.334.705.505.004.504.506.640.00
Intangible Assets6,258.856,472.027,171.177,487.108,979.943,153.353,360.993,658.963,926.66
Deferred Tax Assets869.13560.25477.83376.25311.10254.92221.4057.8834.56
Other Assets102.28119.64240.75150.0396.7526.4650.8445.6424.09
Total Assets11,659.3412,012.2611,393.3610,835.2512,298.646,535.905,538.905,203.495,123.67
Short Term Debt Incl. Current Port. of LT Debt1,044.6245.78624.4046.9446.76260.7846.1233.3940.60
Accounts Payable122.0677.87102.7590.76100.3026.9547.5540.6024.37
Income Tax Payable56.3918.7635.077.729.6125.2010.961.2021.58
Other Current Liabilities1,019.45896.17774.47787.78652.63340.82259.87270.30207.40
Total Current Liabilities2,242.521,038.571,536.69933.19809.30653.75364.49345.49293.95
Long Term Debt4,382.696,121.145,172.255,770.396,112.411,988.551,725.101,563.031,540.43
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities594.47676.74847.71944.341,300.54130.40224.09309.10383.47
Other Liabilities121.0882.0599.71101.60111.19103.46114.23228.46192.72
Total Liabilities7,340.767,918.507,656.367,749.528,333.452,876.162,427.922,446.072,410.57
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity4,318.584,093.763,737.003,085.733,965.193,659.743,110.982,757.422,713.10
Total Shareholders Equity4,318.584,093.763,737.003,085.733,965.193,659.743,110.982,757.422,713.10
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity4,318.584,093.763,737.003,085.733,965.193,659.743,110.982,757.422,713.10
Total Liabilities & Stockholders Equity11,659.3412,012.2611,393.3610,835.2512,298.646,535.905,538.905,203.495,123.67
Book Value Per Share70.3067.5260.0348.8164.3465.1555.4147.9545.30
Tangible Book Value Per Share-31.58-39.23-55.16-69.63-81.369.02-4.45-15.68-20.26
Full-Time Employees2,8902,8002,8002,8003,2001,9401,6201,3601,210
Price to Book Ratio3.801.782.223.651.982.532.692.593.27
Return on Assets-3.014.793.73-1.94-3.503.959.748.669.83
Return on Equity-8.4714.3112.16-6.36-8.657.0517.8416.3521.25
Return on Invested Capital-4.095.484.66-2.53-3.274.2210.8210.3511.47
Quick Ratio1.673.991.741.931.844.204.263.423.15
Current Ratio1.864.462.122.703.174.344.473.573.29

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income205.95-356.15560.12414.83-224.06-329.67477.23523.37447.10
Depreciation718.57696.30660.07638.70629.47552.48278.25370.16216.73
Other Funds (Non Cash)1,147.551,441.70460.77503.131,148.91534.45366.54269.57194.20
Funds from Operations1,859.061,336.871,472.631,296.451,262.07826.46985.09926.49769.21
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-166.5418.90-76.72-204.449.90-47.95-85.44-150.0823.29
Income Taxes Payable-31.8837.22-14.7425.22-1.69-15.5213.0410.06-19.73
Cash from Operating Activities1,692.521,355.771,395.911,092.011,271.98778.51899.65776.40792.50
Capital Expenditures-201.43-167.25-38.07-23.96-54.05-45.53-379.25-182.34-131.47
Net Assets From Acquisitions--858.050.000.000.00-6,234.790.00-55.070.00
Sale of Fixed Assets and Businesses31.3728.170.000.0053.000.0014.2614.2147.90
Purchase or Sale of Investments-100.10-470.27-460.12-120.10-1.041,068.18-642.6767.90-310.92
Purchase of Investments-2,020.10-1,830.28-1,305.12-390.10-61.04-26.82-2,397.68-917.10-1,165.91
Sale Or Maturity of Investments1,920.001,360.00845.00270.0060.001,095.001,755.00985.00855.00
Other Uses-77.00-42.50-10.00-19.00-444.150.000.000.000.00
Other Sources200.000.000.000.000.000.000.000.00-
Cash from Investing Activities-977.96-1,509.91-508.19-163.06-446.23-5,212.14-1,007.67-155.30-394.49
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock-73.61-17.16-290.78-223.3097.97135.26-46.86-243.62-430.33
Repurchase of Common Pref Stock-225.00-125.02-311.43-269.76-0.050.00-146.54-301.45-523.67
Sale of Common Pref Stock151.39107.8620.6546.4698.02135.2699.6857.8393.34
Proceedsfrom Stock Options0.000.000.000.000.000.000.000.000.00
Issuance or Reduction of Debt, Net194.85-781.00369.05-31.00-582.013,870.86591.81-33.39-25.72
Change in Long Term Debt194.85-781.00369.05-31.00-582.013,870.86591.81-33.39-25.72
Issuance of Long Term Debt1,225.900.00980.770.000.005,191.461,481.380.000.00
Reduction of Long Term Debt-1,031.05-781.00-611.72-31.00-582.01-1,320.60-889.58-33.39-25.72
Net Financing Active Other Cash Flow-125.10-75.22-57.75-50.95-45.44-35.60-16.88-16.74-16.67
Other Financing Activities Uses-125.10-75.22-57.75-50.95-45.44-35.60-16.88-16.74-17.93
Cash from Financing Activities-3.86-873.3820.52-305.25-529.493,970.52528.07-293.75-472.72
Exchange Rate Effect-0.376.55-1.681.14-6.22-3.210.370.37-1.70
Net Change in Cash710.33-1,020.97906.55624.83290.03-466.32420.43327.72-76.41
Free Cash Flow1,621.791,297.021,357.841,068.051,242.93750.87884.64736.27772.13
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow9.247.995.998.308.0210.1310.5411.679.83
Deferred Taxes & Investment Tax Credit--444.97-208.33-260.22-292.2569.20-136.94-236.61-88.81

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments2,856.402,199.802,874.302,441.902,046.071,669.88
Short Term Receivables873.70880.90836.30830.75764.36714.00
Inventories454.00443.00437.50416.96483.11504.99
Other Current Assets429.30444.50435.00476.44462.33461.56
Total Current Assets4,613.403,968.204,583.104,166.043,755.883,350.43
Net Property, Plant & Equipment292.00264.10258.90258.74250.12248.06
Total Investments and Advances15.604.304.304.304.304.30
Intangible Assets5,976.505,829.306,008.806,258.856,393.226,612.96
Deferred Tax Assets998.70926.40907.00869.13846.17602.90
Other Assets101.5088.6097.50102.28106.80125.49
Total Assets11,997.7011,080.9011,859.6011,659.3411,356.4910,944.14
Short Term Debt Incl. Current Port. of LT Debt1,032.201,030.701,045.401,044.621,043.121,042.36
Accounts Payable380.30128.50100.00122.06152.2389.37
Income Tax Payable59.2055.9093.7056.3991.1478.55
Other Current Liabilities1,061.501,015.701,007.501,019.45987.62860.93
Total Current Liabilities2,533.202,230.802,246.602,242.522,274.102,071.20
Long Term Debt4,612.803,378.604,371.504,382.694,385.414,390.72
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities506.10528.90547.70594.47629.03682.12
Other Liabilities153.80140.90161.50121.08108.9193.73
Total Liabilities7,805.906,279.207,327.307,340.767,397.457,237.78
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity4,191.804,801.704,532.304,318.583,959.033,706.36
Total Shareholders Equity4,191.804,801.704,532.304,318.583,959.033,706.36
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity4,191.804,801.704,532.304,318.583,959.033,706.36
Total Liabilities & Stockholders Equity11,997.7011,080.9011,859.6011,659.3411,356.4910,944.14
Book Value Per Share65.3974.1072.2970.3065.1861.12
Tangible Book Value Per Share-27.84-15.86-23.55-31.58-40.08-47.93
Full-Time Employees---2,890--
Price to Book Ratio3.803.332.692.612.161.57
Return on Assets1.768.540.25-3.01-3.12-3.63
Return on Equity5.0522.110.68-8.47-9.06-10.84
Return on Invested Capital-5.492.363.292.343.01-8.87
Quick Ratio1.641.581.851.671.441.37
Current Ratio1.821.782.041.861.651.62

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-483.40192.80293.10203.45251.41-718.47
Depreciation178.90179.10181.40179.17178.25174.01
Other Funds (Non Cash)842.70176.9012.00115.95185.521,026.85
Funds from Operations493.40510.10420.30435.26343.77415.97
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital12.70-94.40-12.10-72.74130.85-327.12
Income Taxes Payable3.20-37.7037.40-34.7812.7446.28
Cash from Operating Activities506.10415.70408.20362.52474.6288.86
Capital Expenditures-93.40-18.10-19.70-70.23-45.17-12.97
Net Assets From Acquisitions-830.80--0.000.00-858.05
Sale of Fixed Assets and Businesses3.200.000.0028.170.000.00
Purchase or Sale of Investments-240.00450.0020.00-330.10-240.12230.00
Purchase of Investments-740.00-270.00-500.00-510.10-640.12-240.00
Sale Or Maturity of Investments500.00720.00520.00180.00400.00470.00
Other Uses77.20-77.00-77.200.00-42.500.00
Other Sources0.000.00200.000.000.000.00
Cash from Investing Activities-1,083.80354.90123.10-372.16-327.80-641.02
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-214.4022.7032.9085.190.73-114.53
Repurchase of Common Pref Stock-225.000.000.000.000.00-125.02
Sale of Common Pref Stock10.6022.7032.9085.190.7310.50
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net1,218.10-1,007.70-7.80-7.75-7.75-7.75
Change in Long Term Debt1,218.10-1,007.70-7.80-7.75-7.75-7.75
Issuance of Long Term Debt1,225.900.000.000.000.000.00
Reduction of Long Term Debt-7.80-1,007.70-7.80-7.75-7.75-7.75
Net Financing Active Other Cash Flow-10.00-9.50-103.60-2.00-3.81-2.25
Other Financing Activities Uses-10.00-9.50-103.60-2.00-3.81-2.25
Cash from Financing Activities993.70-994.50-78.5075.44-10.83-124.53
Exchange Rate Effect0.60-0.60-0.400.030.204.62
Net Change in Cash416.60-224.50452.4065.83136.19-672.07
Free Cash Flow489.90397.60388.50345.79459.4475.89
Price to Free Cash Flow9.2410.519.848.316.085.13

Revenue breakdown

Defitelio/Defibrotide2024: 216.57M 2025: 199.39M
Epidiolex/Epidyolex2024: 972.42M 2025: 1.06B
High Sodium A G Oxybate Product Royalty2024: 217.58M 2025: 211.73M
Modeyso2025: 48.04M
Other Products2024: 11.47M 2025: 14.17M
Other Royalties And Contract2024: 30.21M 2025: 34.01M
Rylaze/Enrylaze2024: 410.85M 2025: 402.92M
Sativex2024: 18.88M 2025: 16.28M
Vyxeos2024: 162.60M 2025: 146.71M
Xyrem2024: 233.82M 2025: 146.03M
Xywav2024: 1.47B 2025: 1.66B
Zepzelca2024: 320.32M 2025: 307.31M
Ziihera2024: 1.05M 2025: 24.81M
Europe2024: 312.71M 2025: 341.12M
Other Countries2024: 96.14M 2025: 94.87M
United States2024: 3.66B 2025: 3.83B

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-309.40%5.8M61.7M894.18K
2026-10-159.40%5.9M62.4M873.21K
2026-09-308.79%5.5M62.4M862.04K
2026-09-157.50%4.7M62.4M875.97K
2026-08-317.42%4.6M62.3M921.57K
2026-08-145.81%3.6M62.2M857.12K
2026-07-315.41%3.4M62.0M865.85K
2026-07-156.34%3.8M60.0M927.56K
2026-06-305.84%3.5M60.0M942.29K
2026-06-156.58%3.9M59.9M920.13K
2026-05-297.17%4.3M59.9M899.76K
2026-05-158.10%4.8M59.9M999.61K
2026-04-308.56%5.1M59.5M938.12K
2026-04-158.99%5.2M58.3M927.86K
2026-03-3111.19%6.5M58.3M1.03M
2026-03-1310.57%6.2M58.3M1.03M
2026-02-2710.29%6.0M58.3M1.06M
2026-02-1310.37%6.0M58.3M1.17M
2026-01-309.78%5.7M57.9M1.21M
2026-01-159.24%5.4M57.9M1.16M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call15096.80100.70.002.2930.000.000.932-0.7320.051
call15591.7095.700.002.1910.000.000.928-0.7230.053
call16086.7090.700.002.0690.000.000.924-0.7130.055
call16581.8085.700.001.9310.000.000.920-0.7030.057
call17076.8080.700.001.8170.000.000.916-0.6920.060
call17571.8075.700.001.7050.000.000.911-0.6800.062
call18066.8070.600.001.6140.000.000.905-0.6670.065
call18561.8065.600.001.5060.000.000.899-0.6530.068
call19056.8060.600.001.4000.000.000.893-0.6390.071
call19551.9055.8023.201.2961.000.000.885-0.6230.075
call20046.9050.7032.501.19320.000.000.875-0.6180.079
call21036.9040.9023.521.00430.000.000.854-0.5770.088
call22027.1031.1026.000.8252560.000.823-0.5370.100
call23017.8021.1018.500.6362552.000.781-0.4630.114
call2408.1012.2010.550.48289.003.000.688-0.4010.137
call2502.705.002.550.30549.000.000.466-0.3170.154
call2600.101.850.450.37541.000.000.236-0.2680.119
call2700.001.802.150.5454.000.000.144-0.2670.088
call2800.003.500.950.6791.000.000.141-0.3350.086
call2900.003.500.770.8101.000.000.123-0.3630.078
call3000.003.500.000.9610.000.000.108-0.3860.071
call3100.003.400.001.0420.000.000.101-0.4040.068
call3200.003.400.001.1780.000.000.092-0.4200.063
call3300.003.400.001.2700.000.000.086-0.4350.061
call3400.003.400.001.3670.000.000.082-0.4480.058
call3500.003.400.001.4630.000.000.077-0.4580.056
call3600.003.400.001.5440.000.000.074-0.4700.054
call3700.003.400.001.6100.000.000.068-0.4530.051
put1500.003.400.002.3140.000.00-0.057-0.5740.044
put1550.003.400.001.9810.000.00-0.048-0.4250.038
put1600.003.400.432.22526.000.00-0.074-0.6810.054
put1650.003.400.002.1010.000.00-0.078-0.6700.057
put1700.003.400.001.9810.000.00-0.083-0.6590.059
put1750.003.400.051.7624.001.00-0.078-0.5610.057
put1800.003.400.491.6512,0010.00-0.083-0.5500.059
put1850.003.400.271.5091.000.00-0.085-0.5090.060
put1900.003.400.001.4040.000.00-0.091-0.4980.063
put1950.003.401.821.3303.000.00-0.101-0.5120.068
put2000.003.500.751.2274660.00-0.109-0.4970.072
put2100.053.502.001.11746.000.00-0.146-0.5540.088
put2200.003.600.400.91332.000.00-0.177-0.5130.100
put2300.053.601.030.69612.003.00-0.219-0.4380.114
put2400.404.100.000.5020.000.00-0.312-0.3740.137
put2502.757.007.500.4020.002.00-0.534-0.2890.154
put26010.4014.000.000.4280.000.00-0.764-0.2390.119
put27019.8023.700.000.5850.000.00-0.829-0.2730.098
put28029.6033.600.000.7150.000.00-0.859-0.3040.086
put29039.5043.500.000.8510.000.00-0.877-0.3310.078
put30049.5053.500.000.9640.000.00-0.890-0.3520.073
put31059.5063.500.001.0800.000.00-0.900-0.3710.068
put32069.5073.500.001.1900.000.00-0.907-0.3860.064
put33079.5083.500.001.2940.000.00-0.913-0.4000.061
put34089.5093.500.001.3940.000.00-0.918-0.4120.059
put35099.50103.50.001.4880.000.00-0.922-0.4230.056
put360109.5113.50.001.5790.000.00-0.925-0.4330.054
put370119.5123.50.001.7160.000.00-0.928-0.4420.053

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-104Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-11-06144Filing for proposed sale of securities under Rule 144.SEC
2026-11-064Statement of changes in beneficial ownership of securities2026-11-04SEC
2026-11-054Statement of changes in beneficial ownership of securities2026-11-03SEC
2026-11-05SCHEDULE 13G/ASEC
2026-11-04144Filing for proposed sale of securities under Rule 144.SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-03144Filing for proposed sale of securities under Rule 144.SEC
2026-11-02144Filing for proposed sale of securities under Rule 144.SEC
2026-11-0210-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-028-KCurrent report2026-11-02SEC
2026-10-268-KCurrent report2026-10-26SEC
2026-10-098-KCurrent report2026-10-06SEC
2026-10-08144Filing for proposed sale of securities under Rule 144.SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-06SEC
2026-10-06144Filing for proposed sale of securities under Rule 144.SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-01144Filing for proposed sale of securities under Rule 144.SEC
2026-09-238-KCurrent report2026-09-23SEC
2026-09-158-KCurrent report2026-09-15SEC
2026-09-144Statement of changes in beneficial ownership of securities2026-09-10SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-10144Filing for proposed sale of securities under Rule 144.SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-08144Filing for proposed sale of securities under Rule 144.SEC
2026-09-08144Filing for proposed sale of securities under Rule 144.SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110018.08M4
2026-10001.85M2
2026-09002.28M3
2026-080020.72M2
2026-07001.44M1
2026-06001.96M3
2026-05004.27M5
2026-04001.14M1
2026-03001.35M2
2026-020012.80M5
2026-010000
2025-12001.18M2
2025-110020.81M6

Institutional holders

Manager% owned
ABSOLUTE INVESTMENT ADVISERS, LLC15.40%
BlackRock, Inc.9.50%
FMR LLC8.54%
VANGUARD PORTFOLIO MANAGEMENT LLC4.83%
VANGUARD CAPITAL MANAGEMENT LLC4.35%
Capital World Investors4.29%
LSV ASSET MANAGEMENT3.29%
FRANKLIN RESOURCES INC3.25%
STATE STREET CORP3.18%
FULLER & THALER ASSET MANAGEMENT, INC.2.61%

Funds

Fund% owned
Columbia Convertible Securities Fund26.19%
Nuveen Floating Rate Income Fund25.73%
Virtus Income & Growth Fund17.59%
Nuveen Floating Rate Income Fund17.49%
Virtus Convertible Fund16.98%
Nuveen Credit Strategies Income Fund12.98%
Global Bond Fund8.12%
Short Duration Fund4.73%
Short Duration Strategic Income Fund4.73%
Virtus Convertible & Income Fund3.94%

OakChart. JAZZ. Cached 15 minutes.